Ponatinib Plus Blinatumomab Outperforms Imatinib Plus Chemotherapy in Newly Diagnosed Adult Patients With Ph-Positive Acute Lymphoblastic Leukemia
Clinical Summary:
- Design/Population: The phase 3 GIMEMA ALL2820 trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL).
- Key Outcomes: Ponatinib plus blinatumomab significantly improved 24-month event-free survival, with higher rates of complete hematologic response, molecular response, and survival without measurable residual disease.
- Clinical Relevance: These findings support ponatinib plus blinatumomab as a chemotherapy-free frontline treatment strategy, demonstrating improved disease control and molecular responses compared with imatinib-based chemotherapy.
According to results from the phase 3 GIMEMA ALL2820 trial, frontline ponatinib plus blinatumomab significantly improved event-free survival (EFS) and molecular responses compared with imatinib plus chemotherapy in newly diagnosed adult patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL), supporting a chemotherapy-free targeted and immunotherapeutic treatment approach.
In this trial, 236 patients were randomized 2:1 to receive either ponatinib plus blinatumomab (n = 158) or imatinib plus chemotherapy (n = 78). Patients were permitted to cross over into the ponatinib plus blinatumomab arm upon persistence or reappearance of measurable residual disease (MRD).
The primary end point was EFS. Key secondary end points included complete hematologic response rate, molecular response rate, overall survival (OS), relapse rate, and hematopoietic stem-cell transplantation rate.
At a median follow-up of 23.7 months, the estimated 24-month EFS rate was 86% in the ponatinib plus blinatumomab arm and 67% in the imatinib plus chemotherapy arm (P < .001). The rate of survival without detectable MRD was 68% and 42% of patients, respectively.
At the end of induction, complete hematologic responses were achieved in 94% of patients in the ponatinib plus blinatumomab arm and 79% of patients in the imatinib plus chemotherapy arm. Following blinatumomab consolidation, molecular responses were observed in 71% and 49% of patients, respecitvely.
Among 31 patients who crossed over from the control group to receive ponatinib plus blinatumomab, 20 patients (64%) subsequently achieved a molecular response.
OS was 90% in the ponatinib plus blinatumomab arm and 85% in the imatinib plus chemotherapy arm. The cumulative incidence of relapse was 5% and 13%, respectively.
At the time of analysis, 19% of patients in the ponatinib plus blinatumomab arm underwent hematopoietic stem-cell transplantation after achieving a first complete hematologic response.
These findings demonstrate that combining ponatinib with blinatumomab improved disease control and molecular responses compared with imatinib-based chemotherapy, with relatively limited use of hematopoietic stem-cell transplantation in the investigational arm.
The investigators concluded that the frontline chemotherapy-free combination of ponatinib and blinatumomab was superior to imatinib plus chemotherapy in adults with Ph-positive ALL, supporting the use of targeted therapy and immunotherapy as an alternative to conventional chemotherapy-based treatment.
Source:
Chiaretti S, Piciocchi A, Skert C, et al. Ponatinib–blinatumomab or imatinib–chemotherapy for adult Ph-positive ALL. N Engl J Med. Published online: October 14, 2026. doi: 10.1056/nejmoa2606208


